This application includes a Sequence Listing filed electronically as an XML file named Sequence listing_RONDA-24001-USPT.xml, created on Apr. 26, 2024, with a size of 51,145 bytes. The Sequence Listing is incorporated herein by reference.
The present disclosure belongs to the technical field of animal biology and specifically relates to a sgRNA and constructing a dual pig model of severe immunodeficiency and liver injury and use thereof.
Immunodeficient animals play an important role in the fields of biomedical and basic medical research. Liver transplantation is an important treatment mode for treating end-stage liver failure. Liver donor shortage is a main bottleneck for restricting clinical application of liver transplantation. A hepatocyte transplantation technology is one of important ways for solving the problem of serious shortage of liver organs. Human hepatocytes are implanted into a dual animal model of immunodeficiency and liver injury to produce a humanized liver, and thus the humanized hepatocytes are obtained in batches so as to solve the problem of clinical primary hepatocyte source limitation. The hepatocyte transplantation technology plays an important role in the treatment of diseases caused by human hepatitis B virus (HBV) and hepatitis C virus (HCV), vaccine research and development, pharmacology, toxicology and the like.
At present, by using a dual mouse model of severe combined immunodeficiency disorder (SCID) and urokinase type plasminogen activator (uPA), a mouse, with a humanized liver, having the chimerism as high as 80%, is successfully obtained after 6 weeks of the implantation of human hepatocytes. Based on a FAH−/−/Rag−/−/IL2Rγ−/− triple-gene modified mouse model, a large amount of humanized hepatocytes have been successfully amplified, and the liver regeneration rate can reach 80% or more. However, there are still many problems in the current mouse model:
Pigs are large mammals, and very similar to humans in genome homology, body size, physiological and biochemical indexes, tissue dissection, immune metabolism and the like, such that the establishment of a dual pig model of immunodeficiency and liver injury can be better used in the research of relevant fields of human tumor biology, cell transplantation, immunodeficient models and the like, and has important significance for promoting the rapid development of life science industry.
Aiming at the technical problems and the actual needs, the present disclosure provides a sgRNA and constructing a dual pig model of severe immunodeficiency and liver injury and use thereof. On the basis of a CRISPR/Cas9 gene editing technology, the method simultaneously knock out RAG2, IL2Rγ and FAH genes in a porcine fetal fibroblast to obtain a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited porcine fibroblast cell line, which is used as a donor cell to carry out somatic cell nuclear transfer to construct a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig, and the pathological, immunological, cytological and liver function detection and phenotypic analysis and identification of the cloned pig are further carried out to obtain a dual pig model of severe immunodeficiency and liver injury. The model shows immunodeficiency, liver injury, thymus and spleen dysplasia, reduced mature T cell number, deficiency of B cells and NK cells, and has great advantages and a wide market prospect in the related fields of tumor biology, cell transplantation, humanized animal models and the like.
To realize the above purposes, the present disclosure is realized through the following technical solutions:
The present disclosure provides a RAG2/IL2Rγ/FAH triple-gene targeting vector, a recombinant plasmid for RAG2/IL2Rγ/FAH triple-gene editing of a cell, and a RAG2/IL2Rγ/FAH triple-gene knockout porcine fibroblast cell line.
The RAG2/IL2Rγ/FAH triple-gene targeting vector, wherein the targeting vector is an sgRNA expression vector based on a CRISPR/Cas9 system, and an sgRNA comprises a RAG2-sgRNA, an IL2Rγ-sgRNA, and an FAH-sgRNA; and the sgRNA acts on a site located in a coding region of a pig RAG2 gene, a 5th exon of an IL2Rγ gene, and a 2nd exon of an FAH gene.
Further, the nucleotide sequence of the RAG2-sgRNA is shown in SEQ ID NO: 1; the nucleotide sequence of the IL2Rγ-sgRNA is shown in SEQ ID NO: 2; and the nucleotide sequence of the FAH-sgRNA is shown in SEQ ID NO: 3.
Further, a framework vector is a pGL3-U6-sgRNA (Addgene no: 51133).
The recombinant plasmid for RAG2/IL2Rγ/FAH triple-gene editing of a cell, wherein the nucleotide sequence of the recombinant plasmid RAG2-sgRNA is shown in SEQ ID NO: 4; the nucleotide sequence of the recombinant plasmid IL2Rγ-sgRNA is shown in SEQ ID NO: 5; and the nucleotide sequence of the recombinant plasmid FAH-sgRNA is shown in SEQ ID NO: 6.
Further, the cell is a porcine fibroblast cell line.
The RAG2/IL2Rγ/FAH triple-gene knockout porcine fibroblast cell line, wherein the targeting vector or the recombinant plasmid is transfected into the porcine fetal fibroblast cell line to obtain a targeted positive cell clone, that is the RAG2/IL2Rγ/FAH triple-gene knockout porcine fibroblast cell line or a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited porcine fibroblast cell line.
The present disclosure further provides a method for constructing a dual pig model of severe immunodeficiency and liver injury by using a CRISPR/Cas9 technology. The method uses the CRISPR/Cas9 gene editing technology to knock out RAG2, IL2Rγ and FAH genes in a porcine fetal fibroblast, and uses a somatic cell nuclear transfer technology to construct a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig. The method comprises the following specific steps:
Further, in step 1), the sgRNA comprises a RAG2-sgRNA, an IL2Rγ-sgRNA, and an FAH-sgRNA; wherein the nucleotide sequence of the RAG2-sgRNA is shown in SEQ ID NO: 1; the nucleotide sequence of the IL2Rγ-sgRNA is shown in SEQ ID NO: 2; and the nucleotide sequence of the FAH-sgRNA is shown in SEQ ID NO: 3; and the vector is a framework vector pGL3-U6-sgRNA (Addgene no: 51133).
Further, in step 2), the transfection method comprises lipofection transfection and/or nuclear transfection, preferably nuclear transfection.
Further, in step 3), the donor cell can be a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited single cell clone or a cloned fetal fibroblast and a cloned porcine fibroblast cell.
Further, in step 3), the transfection amount ratio of the pST1374-NLS-flag-linker-Cas9 plasmid and the RAG2/IL2Rγ/FAH-sgRNA=2:1.
Further, in step 3), if batch production of the RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig is required, the pig can be obtained by a continuous cloning technology.
Use of the targeting vector, the recombinant plasmid, the cell or the method in constructing a dual pig model of severe immunodeficiency and liver injury and in the fields of tumor biology, cell transplantation, humanized animal model research and the like.
1. The present disclosure constructs a RAG2−/−/IL2Rγ−/Y/FAH−/− dual pig model of severe immunodeficiency and liver injury on the basis of a CRISPR/Cas9 gene editing technology. Compared with models of rodents such as mice and non-human primates, the pig model is more similar to humans in genome homology, body size, physiological and biochemical indexes, tissue dissection, immune metabolism and the like, has no ethical limitation, plays an important role in the field of human life science research, and has a huge biomedical research application prospect and market value.
2. The present disclosure firstly obtains the dual pig model of severe immunodeficiency and liver injury through the CRISPR/Cas9 technology. The model has a short production cycle and high production efficiency. Besides, after an FAH gene is knocked out, the reversibility can be realized by using an NTBC drug, and thus the problem of irreversible use of the existing model construction technology is solved.
3. In the process of constructing RAG2−/−/IL2Rγ−/Y immunodeficient mice in the prior art, since the immune regulation system of mice is different from that of humans, NK cells cannot be removed after the RAG2−/−/IL2Rγ−/Y knockout. In addition, RAG and IL2Rγ genes are required to be simultaneously edited when the NK cells are removed. Pluralities of genes are knocked out by a zinc finger nuclease and a TALENs technology conventionally, which has the low efficiency. The present disclosure overcomes the efficiency problem of multigene editing through the CRISPR/Cas9 technology. The RAG2−/−/IL2Rγ−/Y/FAH−/− model pig of the present disclosure solves the problem of effectively removing NK cells in peripheral blood, reduces the occurrence of inflammatory reaction to a certain extent, has a higher humanization degree, and effectively reduces immunological rejection to a certain extent.
4. The present disclosure provides sgRNAs suitable for editing three genes of pig FAH, RAG2 and IL2Rγ through activity screening of different sgRNAs and off-target detection, verifies the functions of edited regions after being knocked out, and solves the problems of off-target and low birth efficiency of a cloned animal after polygene modification in the CRISPR/Cas9 gene editing technology.
5. The RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig obtained by the present disclosure shows immunodeficiency, severe liver injury, thymus and spleen dysplasia, reduced mature T cell number, deficiency of B cells and NK cells, high apoptosis rate of hepatocytes, and high immunodeficient degree. The batch production of a dual pig model of severe immunodeficiency and liver injury can be realized by a continuous cloning technology. The construction of the RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited dual pig model of severe immunodeficiency and liver injury has great advantages and potential market application prospects in the related fields of hepatocyte transplantation technology, tumor biology, cell transplantation, humanized animal models and the like.
In order to make the purposes, technical solutions and beneficial effects of the present disclosure more apparent, preferred examples of the present disclosure will be described in detail below to facilitate understanding of those skilled in the art.
The nucleotide sequences of a pig RAG2 gene (Gene ID: 100151744), an IL2Rγ gene (Gene ID: 397156), and an FAH gene (Gene ID: 100623036) were searched in the NCBI database. Aiming at a coding region of the pig RAG2 gene, a 5th exon sequence of the IL2Rγ gene, and a 2nd exon sequence of the FAH gene, targeting gRNA sites were designed and screened by using an online software (http://crispor.tefor.net/), the sgRNAs were ligated to a framework vector to obtain a RAG2-gRNA (SEQ ID NO: 1) targeting vector (
The targeting vectors were co-transfected into a porcine fetal fibroblast, and a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene mutant porcine fetal fibroblast cell line was obtained by screening and was used as a donor cell for somatic cell nuclear transfer to construct a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig (
1. Aiming at the coding region of the pig RAG2 gene (Gene ID: 100151744), the 5th exon sequence of the IL2Rγ gene (Gene ID: 397156), and the 2nd exon sequence of the FAH gene (Gene ID: 100623036), targeting gRNA sites, the RAG2-gRNA (SEQ ID NO: 1), the IL2Rγ-gRNA (SEQ ID NO: 2), and the FAH-gRNA (SEQ ID NO: 3), respectively, were designed and screened.
2. The gRNA sequence SEQ ID NO: 1 of the RAG2 gene was ligated to a GL3-U6-sgRNA framework vector, a recombinant plasmid RAG2-GL3-U6-sgRNA with a correct sequence after sequence verification and a pST1374-NLS-flag-linker-Cas9 plasmid (pST1374-NLS-flag-linker-Cas 9:RAG2-GL3-U6-sgRNA=2:1) were co-transfected into a porcine fetal fibroblast by a nuclear transfection instrument, and 9 single cell clones were obtained by screening, wherein No. 9 single cell clone was RAG2 double allele knockout, named RAG2KO-09, further the RAG2KO-09 single cell clone was used as a donor cell for somatic cell nuclear transfer, a cloned embryo was transferred into a surrogate sow, 6 RAG2KO fetuses were obtained after 35 days, and RAG2KO porcine fetal fibroblast cell lines were isolated (
3. Further, the gRNA sequences SEQ ID NO:2 and SEQ ID NO:3 corresponding to IL2Rγ and FAH genes were respectively ligated to the GL3-U6-sgRNA framework vector, the recombinant plasmids IL2Rγ-GL3-U6-sgRNA and FAH-GL3-U6-sgRNA were obtained by correct sequencing sequences and these two recombinant plasmids and the pST1374-NLS-flag-linker-Cas9 plasmid were co-transfected to the RAG2KO porcine fetal fibroblast through the nuclear transfection instrument to obtain 39 single cell clones in total, and it was screened and identified that No. 25 single clone genotype was a RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene mutant clone (
4. The No. 25 RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited single cell clone screened in step (3) was used as a donor cell for somatic cell nuclear transfer, a cloned embryo was transferred into the uterus of an oestrous surrogate sow, and 2 alive cloned piglets were obtained after 114 days of pregnancy (
Genotype identification: genomic DNA of the 2 alive cloned piglets (RGFP19 and RGFP20) was extracted, the mutation of the RAG2/IL2Rγ/FAH genes of the cloned pig was identified by PCR, T7ENI, Sanger sequencing and the like. The results showed that the pigs were both RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene knockout type (
Phenotypic analysis: the 2 RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene knockout pigs survived 14 days and 29 days respectively (A of
the pigs are large mammals. In the process of preparing a liver injury model, it is a whole-new exploration process to maintain tyrosine metabolism on the pigs by using an NTBC drug. The present disclosure firstly obtains the dual pig model of immunodeficiency and liver injury by a CRISPR/Cas9 technology. Besides, after the FAH gene is knocked out, reversibility can be realized by feeding the NTBC drug. If the batch production of the dual pig model of severe immunodeficiency and liver injury is required, the model can be further obtained by a continuous cloning technology, so as to successfully solve the problem of irreversible use of the existing model construction technology.
The present disclosure determined a dosage regimen of the optimum concentration of the NTBC drug (A of
In conclusion, the present disclosure provides a method for constructing a dual pig model of severe immunodeficiency and liver injury, and overcomes the problems of long production period, low efficiency, irreversible injury, unsatisfactory humanization degree and the like in the existing model construction technology. The obtained RAG2−/−/IL2Rγ−/Y/FAH−/− triple-gene edited cloned pig shows severe immunodeficiency and liver injury, thymus and spleen dysplasia, reduction of mature T cells, deficiency of B cells and NK cells, increased hepatocyte apoptosis, and high immunodeficiency degree. If the batch production of the pig model of severe immunodeficiency and liver injury can be realized through a continuous cloning technology, the model plays an important effect in the related fields of tumor biology, cell transplantation, humanized animal models and the like, and has a potential market application prospect.
Finally, it is noted that the above-mentioned preferred examples are only used to illustrate rather than limit the technical solutions of the present disclosure. Although the present disclosure has been described in detail with reference to the above-mentioned preferred examples, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the present disclosure as defined by the claims.
This application is a continuation-in-part of International Application No. PCT/CN2021/128723, filed on Nov. 4, 2021, which is incorporated herein by reference in its entirety.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/CN2021/128723 | Nov 2021 | WO |
Child | 18646802 | US |